Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 249.36 Million USD | 84.34% |
| 2022 | 135.27 Million USD | -7.09% |
| 2021 | 145.6 Million USD | -9.35% |
| 2020 | 160.62 Million USD | 43.42% |
| 2019 | 111.99 Million USD | 121.48% |
| 2018 | 50.56 Million USD | 7.64% |
| 2017 | 46.97 Million USD | -17.05% |
| 2016 | 56.63 Million USD | -33.11% |
| 2015 | 84.66 Million USD | -10.83% |
| 2014 | 94.95 Million USD | 153.46% |
| 2013 | 37.46 Million USD | 12.1% |
| 2012 | 33.41 Million USD | -64.77% |
| 2011 | 94.86 Million USD | 396.58% |
| 2010 | 19.1 Million USD | 5.44% |
| 2009 | 18.11 Million USD | 23.92% |
| 2008 | 14.62 Million USD | 41.54% |
| 2007 | 10.32 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 258.38 Million USD | -2.0% |
| 2024 Q1 | 263.64 Million USD | 5.73% |
| 2023 Q4 | 249.36 Million USD | 86.69% |
| 2023 FY | 249.36 Million USD | 84.34% |
| 2023 Q2 | 131.11 Million USD | 0.15% |
| 2023 Q3 | 133.57 Million USD | 1.88% |
| 2023 Q1 | 130.91 Million USD | -3.22% |
| 2022 Q4 | 135.27 Million USD | 0.98% |
| 2022 Q3 | 133.96 Million USD | -4.56% |
| 2022 FY | 135.27 Million USD | -7.09% |
| 2022 Q1 | 144.13 Million USD | -1.01% |
| 2022 Q2 | 140.36 Million USD | -2.62% |
| 2021 Q1 | 152.96 Million USD | -4.77% |
| 2021 Q4 | 145.6 Million USD | -3.41% |
| 2021 Q2 | 155.24 Million USD | 1.49% |
| 2021 Q3 | 150.73 Million USD | -2.9% |
| 2021 FY | 145.6 Million USD | -9.35% |
| 2020 Q1 | 100.54 Million USD | -10.22% |
| 2020 FY | 160.62 Million USD | 43.42% |
| 2020 Q3 | 158.74 Million USD | 24.37% |
| 2020 Q4 | 160.62 Million USD | 1.18% |
| 2020 Q2 | 127.63 Million USD | 26.94% |
| 2019 Q4 | 111.99 Million USD | 13.47% |
| 2019 Q2 | 100.21 Million USD | 25.85% |
| 2019 Q1 | 79.63 Million USD | 57.47% |
| 2019 FY | 111.99 Million USD | 121.48% |
| 2019 Q3 | 98.7 Million USD | -1.51% |
| 2018 Q3 | 48.47 Million USD | 7.04% |
| 2018 Q2 | 45.29 Million USD | -4.27% |
| 2018 Q1 | 47.31 Million USD | 0.71% |
| 2018 FY | 50.56 Million USD | 7.64% |
| 2018 Q4 | 50.56 Million USD | 4.31% |
| 2017 Q4 | 46.97 Million USD | -4.63% |
| 2017 Q2 | 57.19 Million USD | 4.97% |
| 2017 Q1 | 54.49 Million USD | -3.78% |
| 2017 FY | 46.97 Million USD | -17.05% |
| 2017 Q3 | 49.25 Million USD | -13.88% |
| 2016 Q3 | 66.31 Million USD | -10.16% |
| 2016 FY | 56.63 Million USD | -33.11% |
| 2016 Q2 | 73.81 Million USD | -5.21% |
| 2016 Q4 | 56.63 Million USD | -14.6% |
| 2016 Q1 | 77.87 Million USD | -8.03% |
| 2015 Q3 | 70.39 Million USD | -2.04% |
| 2015 Q4 | 84.66 Million USD | 20.28% |
| 2015 Q2 | 71.85 Million USD | -80.47% |
| 2015 FY | 84.66 Million USD | -10.83% |
| 2015 Q1 | 367.93 Million USD | 287.49% |
| 2014 Q3 | 98.55 Million USD | 214.1% |
| 2014 Q4 | 94.95 Million USD | -3.65% |
| 2014 Q2 | 31.37 Million USD | -10.79% |
| 2014 Q1 | 35.17 Million USD | -6.12% |
| 2014 FY | 94.95 Million USD | 153.46% |
| 2013 Q2 | 34.7 Million USD | 1.54% |
| 2013 Q1 | 34.17 Million USD | 2.26% |
| 2013 Q4 | 37.46 Million USD | 5.01% |
| 2013 Q3 | 35.67 Million USD | 2.8% |
| 2013 FY | 37.46 Million USD | 12.1% |
| 2012 FY | 33.41 Million USD | -64.77% |
| 2012 Q2 | 26.81 Million USD | 0.0% |
| 2012 Q4 | 33.41 Million USD | 0.0% |
| 2011 FY | 94.86 Million USD | 396.58% |
| 2011 Q4 | 94.86 Million USD | 0.0% |
| 2010 FY | 19.1 Million USD | 5.44% |
| 2010 Q4 | 19.1 Million USD | 0.0% |
| 2010 Q2 | 12.63 Million USD | 0.0% |
| 2009 FY | 18.11 Million USD | 23.92% |
| 2009 Q2 | 15.83 Million USD | 0.0% |
| 2009 Q4 | 18.11 Million USD | 0.0% |
| 2008 Q4 | 14.62 Million USD | 0.0% |
| 2008 FY | 14.62 Million USD | 41.54% |
| 2007 FY | 10.32 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -908912.51% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -2534.391% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -244.095% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -30732.252% |
| Rebus Holdings, Inc. | 5.24 Million USD | -4657.142% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -322.559% |
| Qrons Inc. | 1.48 Million USD | -16650.67% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -20236.549% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -232.848% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -557823.309% |
| Skye Bioscience, Inc. | 14.07 Million USD | -1672.068% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -367.816% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -2502.472% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -59052.83% |
| SQZ Biotechnologies Company | 50.03 Million USD | -398.35% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1976.561% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -6374.733% |
| Mesoblast Limited | 188.44 Million USD | -32.33% |
| Marizyme, Inc. | 26.67 Million USD | -834.818% |
| Genus plc | 485 Million USD | 48.584% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -4168.108% |
| Pharming Group N.V. | 244.07 Million USD | -2.17% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -12305.636% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -9810.052% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -6462.353% |
| ContraFect Corporation | 32.53 Million USD | -666.559% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -12486.1% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -6414.951% |
| IMV Inc. | 37.93 Million USD | -557.398% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -2017.212% |
| MultiCell Technologies, Inc. | 1617.67 USD | -15415244.415% |
| ONE Bio Corp. | 27.49 Million USD | -806.936% |
| Accustem Sciences Inc. | 1.07 Million USD | -23006.041% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -222.112% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -11690.131% |
| Q BioMed Inc. | 8.13 Million USD | -2966.166% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -200.681% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -4745.855% |
| Biomind Labs Inc. | 1.49 Million USD | -16540.024% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -110.044% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -2657.842% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -1255.017% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -17291.463% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -175394.846% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -123892.821% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -4240.013% |
| GB Sciences, Inc. | 5.41 Million USD | -4502.986% |
| Alpha Cognition Inc. | 7.16 Million USD | -3380.492% |
| HST Global, Inc. | 593.59 Thousand USD | -41910.166% |
| CSL Limited | 18.62 Billion USD | 98.661% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -19703.906% |
| Halberd Corporation | 728.71 Thousand USD | -34120.242% |
| Enzolytics Inc. | 365.26 Million USD | 31.73% |
| Agentix Corp. | 2.51 Million USD | -9832.84% |
| Resverlogix Corp. | 67.39 Million USD | -270.006% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -29631.714% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 43.956% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -14448.973% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -907.715% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1994.995% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -6703.772% |
| AVAX Technologies, Inc. | 3.99 Million USD | -6143.999% |
| Zenith Capital Corp. | 27.56 Thousand USD | -904428.282% |
| Genscript Biotech Corporation | 1.32 Billion USD | 81.192% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -104389.932% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -6577.798% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -36527.049% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -9096.254% |
| Kadimastem Ltd | 3.5 Million USD | -7014.946% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -372487.969% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -396.119% |
| BioStem Technologies, Inc. | 15.9 Million USD | -1467.901% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -53562.565% |
| LadRx Corporation | 2.2 Million USD | -11232.253% |
| Cell Source, Inc. | 15.8 Million USD | -1477.617% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4469.2% |
| Regen BioPharma, Inc. | 5.45 Million USD | -4469.2% |
| NovAccess Global Inc. | 7.86 Million USD | -3072.343% |
| Affymax, Inc. | 8.87 Million USD | -2711.063% |
| Itoco Inc. | 1.65 Million USD | -14984.49% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -12055.082% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -4022.49% |
| Mobile Lads Corp. | 1.31 Million USD | -18885.152% |
| CytoDyn Inc. | 127.89 Million USD | -94.981% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -596491.789% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -15820.139% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -2157.699% |
| SYBLEU INC | 681.41 Thousand USD | -36495.927% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -3986.747% |
| International Stem Cell Corporation | 5.27 Million USD | -4625.59% |
| Bioxytran, Inc. | 3.24 Million USD | -7574.085% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -39747.526% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -5300.967% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -508.277% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1020.006% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -12212.185% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -4452.198% |
| Neutra Corp. | 973.52 Thousand USD | -25514.995% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -759.45% |
| PureTech Health plc | 125.58 Million USD | -98.569% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -6537.24% |
| IXICO plc | 1.9 Million USD | -13022.689% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1114.718% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -141.347% |
| CSL Limited | 18.62 Billion USD | 98.661% |